Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

被引：0
|
作者：
Jyoti Velayudhan
Yuh-feng Chen
Amanda Rohrbach
Christina Pastula
Gwen Maher
Heather Thomas
Ryan Brown
Teresa L. Born
机构：
[1] Amgen,
[2] Inc.,undefined
来源：
BioDrugs | 2016年 / 30卷
关键词：
Adalimumab; Human Umbilical Vein Endothelial Cell; Relative Binding; Quality Range; ADCC Activity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：339 / 351
页数：12
相关论文
共 50 条
  • [31] Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
    Shea Jassem
    Wei Wang
    Heather Sweet
    Raffi Manoukian
    Vincent Chow
    Palanisamy Kanakaraj
    Katariina M. Hutterer
    Scott Kuhns
    Ian N. Foltz
    Qing Chen
    John Ferbas
    Helen J. McBride
    Pharmaceutical Research, 2019, 36
  • [32] Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept
    Ribaldone, Davide Giuseppe
    Vernero, Marta
    Astegiano, Marco
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2021, 113 (02) : 155 - 155
  • [33] Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases
    Jin, Ran
    Kruppert, Silvia
    Scholz, Florian
    Bardoulat, Isabelle
    Karzazi, Khalil
    Morand, Francois
    Kricorian, Greg
    Collier, David
    Kay, Jonathan
    RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 523 - 537
  • [34] Supporting extrapolation of indications for ABP 501, the first adalimumab biosimilar: focus on Crohn's disease
    Halder, S.
    Khan, W.
    Wang, X.
    Kuhns, S.
    Sweet, H.
    Reinisch, W.
    McBride, H.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S121 - S121
  • [35] Use of adalimumab biosimilar ABP 501 in Crohn's disease: A real-life experience
    Ribaldone, D. G.
    Vernero, M.
    Pellicano, R.
    Morino, M.
    Saracco, G. M.
    Astegiano, M.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S510 - S511
  • [36] Real-life data on efficacy and safety of original Adalimumab and biosimilar Adalimumab (ABP 501) in pediatric rheumatic diseases
    Ulu, Kadir
    Cakan, Mustafa
    Caglayan, Sengul
    Yigit, Ramazan Emre
    Demir, Ferhat
    Coskuner, Taner
    Kardes, Esra
    Sozeri, Betul
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (08) : 833 - 839
  • [37] Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab
    Seo, Neungseon
    Polozova, Alla
    Zhang, Mingxuan
    Yates, Zachary
    Cao, Shawn
    Li, Huimin
    Kuhns, Scott
    Maher, Gwendolyn
    McBride, Helen J.
    Liu, Jennifer
    MABS, 2018, 10 (04) : 678 - 691
  • [38] LONG TERM EFFICACY AND SAFETY OF ABP 501 ADALIMUMAB BIOSIMILAR ON INFLAMMATORY BOWEL DIESASES: THE ADASWITCH STUDY
    Cingolani, A.
    Felice, C.
    Lombardi, G.
    Onidi, F. M.
    Checchin, D.
    Colucci, R.
    Grossi, L.
    Ferronato, A.
    Rocchi, C.
    Ascolani, M.
    Binaghi, L.
    Dore, M. F.
    Fanini, L.
    Bulajic, M.
    Mocci, G.
    DIGESTIVE AND LIVER DISEASE, 2022, 54 : S138 - S138
  • [39] REAL-WORLD UTILIZATION OF ADALIMUMAB BIOSIMILAR (ABP 501) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN EUROPE
    Jin, Ran
    Nduka, Chidozie
    Courmier, Delphine
    Knight, Hannah
    Meadows, Rachael
    Piercy, James
    Radziszewski, Waldemar
    INFLAMMATORY BOWEL DISEASES, 2022, 28 : S109 - S110
  • [40] RELATIONSHIP BETWEEN PHARMACOKINETICS AND ANTI-DRUG ANTIBODY STATUS OF ABP 501, A BIOSIMILAR CANDIDATE TO ADALIMUMAB
    Kaur, P.
    Chow, V.
    Zhang, N.
    Markus, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 714 - 714
12345